It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
The following technology appraisals have been endorsed during 2020/21. Information on technology appraisals endorsed in previous years can be found on the homepage.
TA681 - Baricitinib for treating moderate to severe atopic dermatitis
TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction
TA677 - Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma
TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis
TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
TA672 - Brolucizumab for treating wet age-related macular degeneration
TA671 - Mepolizumab for treating severe eosinophilic asthma Note this guidance updates and replaces NICE Technology Appraisal TA431, which was endorsed by the DoH in February 2017.
TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
TA669 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
TA665 - Upadacitinib for treating severe rheumatoid arthritis
TA664 - Liraglutide for managing overweight and obesity
TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
TA660 - Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
TA659 - Galcanezumab for preventing migraine
TA658 - Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
TA657 - Carfilzomib for previously treated multiple myeloma Note this guidance has been partially updated and replaced by TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma, which was endorsed by the DoH in May 2021
TA656 - Siponimod for treating secondary progressive multiple sclerosis
TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy Note this guidance updates and replaces NICE Technology Appraisal TA483, which was endorsed by the DoH in January 2019.
TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
TA651 - Naldemedine for treating opioid-induced constipation
TA650 - Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
TA649 - Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
TA645 - Avelumab with axitinib for untreated advanced renal cell carcinoma
TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis
TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
TA631 - Fremanezumab for preventing migraine
‘Note this guidance has been updated and replaced by TA764 - Fremanezumab for preventing migraine, which was endorsed by the DoH in February 2022’.
TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours
NICE TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab Note this guidance updates and replaces NICE Technology Appraisal TA472, which was endorsed by the DoH in January 2019.
NICE TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
NICE TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure